RNS Number : 6849Q
Hemogenyx Pharmaceuticals PLC
08 June 2018
Hemogenyx Pharmaceuticals Plc
(“Hemogenyx” or the “Company”)
Investor presentation
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it will hold a presentation for investors on Tuesday 26th June 2018.
The briefing by Dr. Vladislav Sandler, CEO of Hemogenyx, will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email hemogenyx@walbrookpr.com
Enquiries:
#BBD0E0»
| Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com | |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | |
| Sir Marc Feldmann, Chairman | ||
| Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 | |
| Christian Dennis | ||